Disruption is the overdue remedy and how this debate can revitalise the PBS

The MS medicines controversy continues. Why wouldn’t the minister just deal with it and make it go away? It may not be that easy. Why any resolution will probably deal with symptoms rather than the cause. The realities of ministerial offices and the challenges they face that are not visible to outsiders. Another 'phrase of the week' is dissected to reveal its true meaning.

New research commissioned by GSK Australia suggests many Australians aged 65 years and over do not recognise how seriously respiratory syncytial virus could potentially impact them, despite considering it a serious condition.

Researchers in Melbourne have reported an association between the radiation dose tumours receive during radiopharmaceutical therapy and progression-free survival in patients with metastatic castration resistant prostate cancer.

Officials could communicate the committee's advice from the meeting, as has happened in the past, and the minister could act accordingly. That could involve accepting the advice, making a decision to ensure patients maintain reimbursed access, as he has prioritised, or both. Probably best to resolve it quickly for patients.

A $680,000 partnership between Diabetes Australia, Lilly Australia and the Menzies School of Health Research will expand a digital health platform aimed at improving care for people with diabetes, kidney and cardiovascular disease across the Northern Territory.

Illumina has appointed Susan Martin as General Manager for Australia and New Zealand, strengthening the company’s regional leadership as it pushes to integrate genomics more broadly into clinical care.

When he was announcing the PBS listing of one of these at-risk MS medicines late last year, having presumably been told that any price reduction would put it at risk, officials were probably well and truly in the process of manoeuvring the provider of another off-patent medicine brand into accepting an almost 50 per cent cut.

Health Minister Mark Butler has said the government is not attempting to price two recently listed medicines at the same level as old off-patent treatments, and has reminded officials and the PBAC that he expects them to remain on the PBS.

Aegros' chief executive, Damian Thornton, a 35‑year industry veteran brought in after a financial and board restructure, said the company’s 2025 capital raise was pivotal in addressing prior debt issues and unlocking completion of the facility without further government funding beyond R&D tax incentives.

AusBiotech CEO Rebekah Cassidy said, “Let’s be clear, while the changes aren’t due to take effect until 2028, they are already influencing decisions. Our sector is urgently seeking a meeting with the Treasurer and a consultation process to bring forward a resolution."

Terms like 'independent experts', 'evidence-based decision making', and 'value' have been consistently invoked for decades in response to criticism. They sound reasonable. The truth is that they are meaningless, highly subjective rhetorical shields that primarily serve to disarm criticism and hobble discussion. The proposed reforms to trade agreements negotiations is an attempt to create another shield to hobble discussions.

Australian Healthcare Associates has been reappointed to continue as the Administration Agency for the Community Service Obligation Funding Pool under the First Pharmaceutical Wholesaler Agreement.

Australia’s largest life sciences private equity company, Brandon Capital, has announced a landmark exit as Novartis moves to acquire its portfolio company Myricx Bio in a deal valued at up to US$1.5 billion, including an upfront cash payment of US$1.1 billion and further milestone payments. 

A small player with no market share and no real prospect of gaining any agreed to an almost 50 per cent price reduction to secure reimbursement. Who would have thought the market leaders, on whom patients rely, would respond negatively? Discussion about the change to nurse prescribing, which has been a feature of the PBS for more than 15 years, and concerns over vaccine hesitancy.

The Bill would reform how the Australian government negotiates trade agreements and limit certain ministerial powers, notably removing the authority to agree to the inclusion of investor-state dispute provisions and anything that would 'undermine the integrity' of the Pharmaceutical Benefits Scheme.

The Albanese Government’s proposal to legislate that a trade minister may not accept any inclusion in a trade agreement that “could undermine the integrity of the PBS” is performative, meaningless theatre that would not prevent any response to the 'Most Favored Nation' pricing policy through the one agreement that matters.

A major international study has found that obese middle-aged and older adults now face a similar risk of heart attack to that of their slimmer and healthy counterparts, with bad cholesterol in obese over-60s now lower than in some people with a normal body mass index.

There was no concession of the need for change. However, the 'no concessions' rhetoric that has dominated Australian responses to US interest in the PBS for so many years was set aside in favour of language acknowledging the challenge.

The Medicines Australia chief concedes the conversation gets uncomfortable when it turns to pricing, but argues the alternative is worse. “Sometimes it is an uncomfortable conversation to talk about fair pricing, but it is not as uncomfortable as delays and medicine departures are for patients fearing for their health.”

According to the Indian proverb, 'nothing grows beneath a banyan tree'. The tree is strong and stable. Yet its root system monopolises the soil and water, which, combined with the dense light-blocking shade of its canopy, kills off everything beneath it. Sounds like something else.